<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04165603</url>
  </required_header>
  <id_info>
    <org_study_id>2018PHB144-01</org_study_id>
    <nct_id>NCT04165603</nct_id>
  </id_info>
  <brief_title>Fluorescence-navigated Thoracoscopy for Detection of Small Pulmonary Nodules</brief_title>
  <official_title>Fluorescence-navigated Thoracoscopy for Detection of Small Pulmonary Nodules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fluorescence-navigated thoracoscopic imaging with indocyanine green (ICG) is a novel
      technique for detection of small pulmonary nodules other than traditional radiography or
      intraoperative palpation. As a non-targeted fluorescent contrast agent, ICG accumulates in
      tumors by the enhanced permeability and retention effect (EPR), making the lesions fluoresce
      under fluorescent imaging. However, the optimal dosage and injection time of ICG are still
      under exploration. Hence, we perform this study in humans made up of four groups to determine
      the optimal time and dose.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Signal-to-background Ratio (SBR) of the Tumor and Normal Parenchyma</measure>
    <time_frame>within 1 week after surgery</time_frame>
    <description>We use image analysis software ImageJ to evaluate the strength of luminosity in tumors and normal parenchyma using intraoperative images and calculate signal-to-background-ratios.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">352</enrollment>
  <condition>Pulmonary Nodule, Solitary</condition>
  <condition>Pulmonary Nodule, Multiple</condition>
  <arm_group>
    <arm_group_label>5mg/kg of ICG, 24h before surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5mg/kg of indocyanine green, intravenously injection 24 hours before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1mg/kg of ICG, 24h before surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg/kg of indocyanine green, intravenously injection 24 hours before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5mg/kg of ICG, 48h before surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg/kg of indocyanine green, intravenously injection 48 hours before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1mg/kg of ICG, 48h before surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg/kg of indocyanine green, intravenously injection 48 hours before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Preoperative Infusion of Indocyanine Green</intervention_name>
    <description>preoperatively infuse indocyanine green through peripheral vein</description>
    <arm_group_label>1mg/kg of ICG, 24h before surgery</arm_group_label>
    <arm_group_label>1mg/kg of ICG, 48h before surgery</arm_group_label>
    <arm_group_label>5mg/kg of ICG, 24h before surgery</arm_group_label>
    <arm_group_label>5mg/kg of ICG, 48h before surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Peripheral pulmonary solid nodules, with diameter 1-3 cm.

          -  Suitable for surgery and signed informed consent.

        Exclusion Criteria:

          -  Liver dysfunction.

          -  Allergic to indocyanine green.

          -  Can't tolerate thoracoscopic surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang Jun, MD</last_name>
    <role>Study Director</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Yang, MD</last_name>
    <phone>(+86) 18612978269</phone>
    <email>yangfeng1007@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tiezheng Li, MD</last_name>
    <phone>(+86) 18811768786</phone>
    <email>tiezhengli@foxmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Yang, MD</last_name>
      <phone>+8618612978269</phone>
      <email>yangfeng1007@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 10, 2019</study_first_submitted>
  <study_first_submitted_qc>November 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>November 13, 2019</last_update_submitted>
  <last_update_submitted_qc>November 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Jun Wang</investigator_full_name>
    <investigator_title>Chiefï¼ŒThoracic Surgery Service</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Pulmonary Nodules</mesh_term>
    <mesh_term>Solitary Pulmonary Nodule</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

